Akums Drugs
Drug Manufacturers - Specialty & Generic · AKUMS
Mid CapHealthcareHigh Growth
Sanjeev Jain
Managing Director · Visionary
Company DNA
Performance-Driven
About
Akums Drugs is a Mid Cap company in the Healthcare sector, listed on NSE as AKUMS. With a market cap of ₹8K Cr and revenue of ₹4K Cr, it is currently in the High Growth phase. Known for its Performance-Driven culture and Fast-Follower approach to innovation, the company operates at a Startup-Speed pace. High growth, volume-driven generic manufacturing environment requiring intense operational rigor. Its strategic mandate: Needs to drive R&D-led growth and portfolio expansion to capitalize on its position as a major contract manufacturer.
FAQ
What kind of company is Akums Drugs?
Akums Drugs is a Mid Cap Healthcare company (AKUMS) in the High Growth phase with a market cap of ₹8K Cr. It is classified as Performance-Driven in culture.
What is Akums Drugs's culture and work environment like?
Akums Drugs has a Performance-Driven culture with Fast-Follower innovation DNA and a Startup-Speed pace of execution. Employee brand: Demanding Machine. Customer relationship style: B2B-Enterprise. High growth, volume-driven generic manufacturing environment requiring intense operational rigor.
Who leads Akums Drugs?
Akums Drugs is led by Sanjeev Jain (Managing Director), a Visionary leader with 40 years of experience.
What are Akums Drugs's financials?
Akums Drugs reported revenue of ₹4K Cr in FY25 with a 5-year revenue CAGR of 3.7%. Operating margin: 7.6%. Market cap: ₹8K Cr.
Culture & Strategy
CulturePerformance-Driven
InnovationFast-Follower
PaceStartup-Speed
PurposeProfit-Pure
CustomerB2B-Enterprise
EmployeeDemanding Machine
BrandTechnical-Expert
LifecycleHigh Growth
High growth, volume-driven generic manufacturing environment requiring intense operational rigor.
Mandate
Needs to drive R&D-led growth and portfolio expansion to capitalize on its position as a major contract manufacturer.
Needs to drive R&D-led growth and portfolio expansion to capitalize on its position as a major contract manufacturer.
Financials
Revenue FY25₹4K Cr
PAT FY25₹338 Cr
Rev CAGR 5Y3.7%
OPM7.6%
NPM8.3%
ROE11.1%
ROCE9.6%
P/E22.5
Fwd P/E19
P/B2.3
D/E2.9
Mkt Cap₹8K Cr
Promoter84.9%
Institutional13.6%
Similar Culture
Could You Lead Akums Drugs?
Take the Genome Benchmark →